-----:0
Expresses the sense of the Senate that: (1) the Department of Health and Human Services should identify and research hypertension in racial minority groups; (2) the Centers for Disease Control and Prevention should conduct hypertension surveillance in racial minority groups; and (3) the National Heart, Lung, and Blood Institute should develop a curriculum on hypertension.
-----:1
This bill amends the Federal Food, Drug, and Cosmetic Act to permit the Food and Drug Administration to issue a regulation that modifies the labeling of food to include certain information regarding the relationship between food and prostate cancer. Specifically, the FDA must provide certain information regarding the relationship between tomato products and prostate cancer, including a review of existing studies and a recommendation that may be appropriate for clinical use.
-----:2
Chronic hcv infection and liver fibrosis: A descriptive study - Amends the Public Health Service Act to expand the definition of chronic hcv infection to include pnalnalt portal infection and liver fibrosis. Defines: (1) "chronic hcv infection" as infection that is confined to the liver; and (2) "pnalt portal infection" as infection that is present in the liver, but not the end stage of liver disease. Provides guidelines for determining the value of pnalt portal infection and the duration of infection.
-----:3
Replaces the current requirement that blood donors be screened for hepatitis A, B, and C with a requirement that blood donors be screened for hepatitis C, D, and other viral pathogens before use of blood plasma from a donor. Sets forth additional requirements for replacement blood donors, including that: (1) the blood must be stored for at least 24 hours; (2) the donor must be informed of the risk of transmission of bloodborne pathogens; and (3) the hospital must comply with certain reporting requirements.

Directs the Secretary of Health and Human Services, acting through the Administrator of the Health Resources and Services Administration (HRSA), to assist eligible nations in making improvements in the method for screening blood donors for hepatitis A, B, and C. Requires the Secretary to establish certain guidelines for the screening of replacement blood donors.

Requires the Secretary to report to Congress on the implementation and impact of this requirement on safe blood procurement.
-----:4
protein interaction network analysis - Provides for the development of a protein interaction network to enable the search of protein pathways within a genome for interaction patterns between species, based on the identification of proteins within such a network that have not been reported on the Internet.
-----:5
Disulfiram should be used at the lowest effective dose, possibly 250 mg per day, only while prescribing first therapeutic intake of 250 mg per day, and then at the lowest effective dose of 500 mg per day, followed by a maintenance dosage of 250 mg per day for up to ten days, at the lowest effective dose of 250 mg per day, which should be administered before the first therapeutic intake.
-----:6
Environmental Protection Agency (EPA) - Authorizes the use of a new chemical weapon to control malfestina insects, which are considered to be a threat to human health because of their ability to transmit dangerous diseases to other animals. Directs the EPA to: (1) consider the effects of the use of such a chemical on human health and welfare, (2) adjust the level of exposure to ensure that the insects do not adapt to the new weapon, (3) give priority to determining the best method to use the new weapon, and (4) report information regarding the use of such weapon and any adverse effects.
-----:7
Directs the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention (CDC), to: (1) undertake a national assessment of the incidence and prevalence of osteoporosis in Korea, and (2) provide grants to research institutions in Korea to evaluate the incidence and prevalence of osteoporosis in Korean women.
-----:8
Directs the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention (CDC), to: (1) monitor the level of srage (a variant of the full length or a shedding product of membrane bound to a cell surface) in the blood of individuals with diabetes and other non-elderly individuals (and subjects with diabetes) who were enrolled in the study, and (2) monitor the level of srage in the blood of individuals who were treated with srage (either pre-diabetes or post-diabetes), taking into account the differences between the populations.
Requires the Secretary to: (1) issue guidelines for the provision of srage treatment to individuals with diabetes and other non-elderly individuals, including advice to health care providers on how to determine the appropriateness of patient treatment with srage; and (2) maintain and update a database of data on diabetes cases reported to the CDC.
-----:9
Directs the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to ensure that the safety and effectiveness of the automated method of correcting myopia (the use of an implantable lens) are demonstrated through ongoing clinical and research studies in the United States and internationally.
-----:10
Small cell carcinoma of the bladder - Title I: Treatment of Small Cell carcinoma of the bladder
 - Amends the Federal Food, Drug, and Cosmetic Act to revise the definition of "small cell carcinoma of the bladder" to include new tumors that are not categorized as transurethical carcinoma. 
Title II: Treatment of Small Cell carcinoma of the bladder
 - Modifies the definition of small cell carcinoma to include new tumors that are transurethical carcinoma and are not categorized as such. 
Title III: Treatment of Small Cell carcinoma of the bladder
 - Modifies the definition of small cell carcinoma to include new tumors that are transurethical carcinoma and are not categorized as such.
-----:11
Prohibits the formation of newvascular abnormalities in the navies orduras, or thejoining of any newvascular abnormalities between the navies andduras.
Declares that nothing in this Act shall be construed to modify the treatment of pneumoconiosis or other chronic disease of the navies orduras.
-----:12
medblastoma is a malignant tumor of the central nervous system that is primarily composed of patrilineal cells and may be associated with human polyoma virus or medullosis. Authorizes the Secretary of Health and Human Services to provide assistance to the National Institutes of Health in furtherance of this association through the provision of technical assistance in furtherance of research.
-----:13
This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to revise the requirements for the labeling of certain drugs to assess the activity of bexal against a broad range of contemporary pathogens, including the following pathogens: salmonella, a naturally occurring infection caused by the mycocardiailiensis yeast; enterococcus, a fungal infection caused by the enterococcus faecococcus; and tuberculosis, a disease-related infection caused by the tuberculosis virus. The FDA must issue guidance on the labeling of a drug that is a combination of bexal and certain antibiotics, including those that contain benzotoic acid and are used to treat infections caused by pathogens. The Centers for Disease Control and Prevention must report on changes in the risk factors for infections caused by these pathogens. These changes must be associated with a strategy to reduce the incidence of infections resulting from antimicrobial resistance.
-----:14
Allows the use of a combination of soft tissue and synthetic modalities to treat the causes of femorotabular impingement in a professional athlete.
Directs the Secretary of Health and Human Services to: (1) support the development of new surgical approaches to treat femorotabular impingement, to include the use of a combination of soft tissue and synthetic modalities, to improve the quality of life for such patients, and to ensure that such treatments are effective; and (2) conduct a study to determine the extent to which femorotabular impingement can be treated with non-operative methods.
-----:15
Obesity and Nutrition of Old Age and Survivors in salmas district, Afghanistan. - Amends the Foreign Assistance Act of 1961 to authorize the President to provide assistance for a program to reduce obesity and nutrition of old age and survivors in salmas district, Afghanistan.

Directs the President, through the Secretary of State, to establish a panel of experts to: (1) review evidence concerning the effectiveness of U.S. assistance in reducing obesity and nutrition of old age and survivors in salmas district, Afghanistan; (2) identify gaps in research and programs needed to improve the nutrition of such children; and (3) make recommendations to the President regarding the development of a comprehensive program to reduce obesity and nutrition of old age and survivors in salmas district.
-----:16
Prohibits the use of a human embryo for breeding unless the embryo has been treated with pnfnf-1 or pnfnf-1-related dysplasia.
-----:17
Directs the Secretary of Health and Human Services, acting through the Administrator of the Health Resources and Services Administration, to expand, intensify, and coordinate the program known as the National Cancer Institute's Early Detection and Treatment Initiative.
-----:18
American Society for Cell Transplantation - Requires the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, to review the guidelines issued by the Food and Drug Administration on the use of certain tissues for screening for human clinical tissue loss and other tissue banking activities. Directs the Secretary to ensure that such guidelines are updated to reflect advances in technology and procedures.
-----:19
Directs the Secretary of Health and Human Services (HHS) to convene a panel of experts to review and identify: (1) the current state of the science relating to the diagnosis of pji (a disease of the foot and ankle) and its impact on patient care, and (2) recommendations to improve the accuracy of pji diagnostic tests and improve the management of patients with pji. Requires the Secretary to issue a report that: (1) summarizes the findings of the panel, (2) identifies areas for further research and recommendations, and (3) describes the steps taken to improve the accuracy of pji diagnostic tests and the management of patients with pji.
-----:20
Expresses the sense of the Congress that: (1) the Food and Drug Administration should issue guidance to manufacturers of certain drugs for the treatment of conditions caused by immune system cells in patients undergoing chemotherapy; and (2) the Department of Health and Human Services should conduct a study to determine the extent to which certain drugs may cause adverse effects on the eyes of patients receiving chemotherapy.
-----:21
Directs the Secretary of Health and Human Services to establish a grant program to provide assistance to universities and research institutions in developing programs to increase the understanding of the bonding properties of various organic chemicals. Authorizes appropriations.
-----:22
This bill authorizes the National Institutes of Health to expand the understanding of the role of certain transcription factors in human immune system response to autoimmune diseases, by examining the role of certain transcription factors in the initiation and maintenance of these immune responses.
-----:23
Macrolides (anti-and antimicrobial resistance defenders) - Amends the Federal Food, Drug, and Cosmetic Act to prescribe guidelines for the marketing of any new drug approved based on this Act that is a member of the macrolides class of antibiotics. Defines "anti- and antimicrobial resistance defender" to mean an antibiotic drug which prevents the growth of bacteria and is not intended to be used to treat diseases. Directs the Secretary of Health and Human Services to issue regulations to define the term " antimicrobial resistance defender."
-----:24
This case report describes a case of pseudozymais fung infiltration, which was reported as an invasive result of chemotherapy after reinduction and was the result of consolidation of isolated ground glass organisms with a specified antifungal drug.
-----:25
Directs the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention (CDC), to provide assistance to the Director of the National Institute of Diabetes and Digestive and Kidney Diseases to conduct and support research into: (1) the relationship between diabetic foot ulcerations and subsequent complications; (2) the mechanisms through which such ulcerations develop; and (3) the treatment of diabetic foot ulcerations.

Directs the Secretary to: (1) conduct and support research to determine the reasons for the higher incidence of diabetic foot ulcerations among patients with end stage renal disease who received hemodialysis; and (2) develop guidelines for the management of such ulcerations.
-----:26
American Heart, Lung, and Blood Institutehibits the use of a specific human gene to treat heart disease if the human gene for that gene is located in the heart muscle and is associated with heart disease. Permits the use of a human gene to treat heart disease if a specific human gene is located in the heart muscle and is associated with heart disease.
-----:27
retinal detachments in patients with chronic vision loss who should have their retinal detachments considered as being at high risk for future vision loss, but who have chosen to undergo surgical repair.
Authorizes the use of azooticoticotic tissue harvested from a donor whose retinal detachment has been removed to reconstruct the visual field of the affected eye.
-----:28
Directs the Secretary of Health and Human Services to award grants to support the continued efforts of the National Institutes of Health to develop new technologies relating to the proteic conversion of proteins of living cells.
-----:29
This bill authorizes the Department of Health and Human Services to award grants to nonprofit private entities to conduct a pilot program to provide information on the effectiveness of ambulatory echocardiography in reducing the incidence of obesity and hypertension in Korean patients who were diagnosed with essential hypertension and enrolled in the study. The grants may be used to: (1) identify specific biomarkers of obesity, cardiovascular disease, and diabetes in the patients; (2) devise a treatment strategy to reduce obesity and hypertension in the patients; and (3) improve access to ambulatory echocardiography in Korea for the purpose of improving public awareness of obesity, cardiovascular disease, and hypertension and providing referrals for medical treatment.
-----:30
dental prosthesis manufacturing system - Provides for the manufacturing of dental prostheses using an automated dental prosthesis manufacturing system that cuts materials in accordance with specified specifications.
-----:31
Prohibits waxing, coloring, or applying a product containing ephedrine or other chemical substances to treat or prevent trichonodosis.
Prohibits applying a product containing any chemical or substance to treat or prevent trichonodosis if it is intended for use in connection with a treatment for human hair or other animal hair.
Prohibits the use of any product that contains any chemical or substance which is intended for treatment of human hair or other animal hair when applied to the human scalp prior to or after a specified appointment at a clinic or hospital.
Requires the manufacturer of any product to provide that the product will not cause any harm to the human scalp if used within a reasonable time before or after a specified appointment at a clinic or hospital.
Prohibits a product from containing any chemical or substance which is intended for treatment of human hair or other animal hair if it is intended for use in connection with a treatment for human hair or other animal hair.
Requires the manufacturer of any product which contains any chemical or substance to provide that the product will not cause any harm to the human scalp if used within a reasonable time before or after a specified examination at a clinic or hospital.
Authorizes the manufacturer of any product which contains any chemical or substance to provide
-----:32
Directs the Secretary of Health and Human Services, acting through the Administrator of the Health Resources and Services Administration, to: (1) take steps to expand the data on the course and incidence of cardiac toxicity in patients with relapsing multiple sclerosis who received mitoxantrone therapy during the period beginning on January 1, 2004, and ending on June 1, 2008; and (2) report to the appropriate congressional committees on such data as may be necessary to ensure the continued availability of such data.
-----:33
Prohibits the use of certain of such subunits to treat human disease or other animals if: (1) the drug is ineffective if it affects one of the subunits; or (2) the drug is intended for use in a non-human animal.
-----:34
Directs the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention (CDC), to: (1) monitor the level of vitamin d in the blood and ensure that vitamin d supplements are properly labeled, (2) monitor the safety of individuals with chronic liver disease who are participating in the clinical trial designed to determine if vitamin d supplementation can reduce the incidence of nafld-related disease, and (3) make available to the public information regarding the clinical trial results and the safety of vitamin d supplements.
-----:35
Directs the Secretary of Health and Human Services to ensure that the American Medical Association Committee on Prostatic enlargement Research continues to review and update the list of items on which a study on the safety and efficacy of the laser prostatic enlargement procedure is based.
-----:36
Multi-disciplinary multi-center clinical trial and report on the treatment of a 66-year old man with a known primary myelofibrosis who was also diagnosed with pulmonary hypertension and whose pulmonary abnormalities were suspected to be caused by extramedry hematopoiesis in the presence of ground diffuse glass and interstitial bone marrow.
-----:37
Directs the Secretary of Health and Human Services, acting through the Agency for Healthcare Research and Quality, to enter into an agreement with the Institute of Medicine to study the impact of certain proteins on human embryos during mitosis, to determine the extent to which these proteins are recruited to or utilized by human embryos during mitosis, and to develop a strategy to address the challenges of recruiting such proteins to or utilized by human embryos during mitosis.
-----:38
Directs the Secretary to conduct or support research, and report to the appropriate congressional committees, on the effectiveness of the National Cancer Institute's melanoma screening program.
-----:39
Prohibits the use of a human embryo for adoptive purposes if the donor has donated the embryo to the United States or its territories for research or production. Limits the use of such a embryo to non-human primates. Requires the Secretary of Health and Human Services to ensure that the embryo is used only for research or production of drugs or other devices that may prevent or treat blindness, or that may provide a method for creating new retinal cells to replace those that have been lost. Permits the Secretary to convene a panel of experts to evaluate the ethical, legal, and other issues related to the use of such an embryo for research or production of drugs or other devices that prevent or treat blindness.
-----:40
This bill authorizes the Centers for Disease Control and Prevention to grant additional funding to research related to biliary hamartomas, after authorizing appropriations under the Public Health Service Act.
-----:41
Human Rights Protection Act of 2016 This bill amends the Foreign Assistance Act of 1961 to require that Department of State country reports on human rights practices for countries that are not complying with international human rights standards include a description of the status of sexual orientation and gender identity within the country's social security, health care, and educational systems. It expresses the sense of the Congress that the United States should support the efforts of countries in Africa and elsewhere to adopt and implement laws that protect the rights of individuals based on their sexual orientation and gender identity, particularly the right to health care and information. The bill also prohibits the U.S. government from providing assistance to Nigeria pursuant to the Foreign Assistance Act of 1961 unless the government is taking certain actions to protect these rights.
-----:42
Elderly nursing facility insurance program in korea - Amends the korean long-term care insurance program to revise the formula for determining the grade of a nursing facility under the program. Establishes the formula based upon a review of data collected from all nursing facilities in all regions of Korea. Requires each facility to report to the government on the frequency of inappropriate medication use by its patients admitted to the facility during the preceding year and the reasons for such use. Prohibits such data from being used to determine the suitability or adequacy of nursing facilities for admission of elderly patients. Requires the government to revise the formula for determining a grade for each type of nursing facility based upon the data collected, taking into account the findings of this report.
-----:43
Expresses the sense of the Congress that: (1) the Secretary of Health and Human Services should support the development of a diagnostic system for extrahec portal hypertension to improve access to medical facilities in developing countries; (2) the Secretary should support the development of a system to determine the prevalence of evovo portal hypertension in developing countries and develop recommendations for improving access to medical facilities for such patients; and (3) the Secretary should coordinate the activities of the United States Agency for International Development regarding evovo portal hypertension.
-----:44
Directs the Secretary of Health and Human Services to ensure that the National Heart, Lung, and Blood Institute has continued to provide support for the research, development, and testing of new technologies related to the repair of heart defects through the use of echocardiograms.
-----:45
Women have a higher risk of developing mesieres than men, but there may be other factors that contribute to this difference.
-----:46
Increases the number of prescriptions written by the students of the control group for the same clinical conditions, but decreases the number of prescriptions written by the students of the control group for non-cancer clinical conditions.
Provides for a comparison of the prescribing skills of the students of the control and the students in the alternative intervention.
-----:47
Washington, D.C. Admission, Health Care, and Community Development Act of 2005 - Amends the federal criminal code to require the Secretary of Health and Human Services to provide admission to the United States, and subsequent admission and discharge from the United States, of individuals who contract tuberculosis (TB) due to exposure to TB in Washington, DC.

Sets forth TB case identification and reporting requirements, including: (1) epidemiological assessment; (2) reporting of TB cases by geographic area; (3) identification of individuals who had TB in the past or who would have TB infections; (4) TB patient education; (5) testing, referral, and treatment; (6) quarantine; (7) community service; and (8) reporting of TB cases to appropriate health care agencies.

Allows the Secretary to identify TB cases and identify individuals who may have TB by examining patient records and identifying TB patients.

Requires the Secretary to: (1) develop and implement a program to notify individuals who may have TB of the benefits of being admitted to the United States; (2) provide TB testing, referral, and treatment through a system that ensures the accuracy of TB test results; (3) develop and implement a program to notify individuals who may have TB of the benefits of being admitted to the United States; and (4) ensure that information from the TB testing system is
-----:48
TABLE OF CONTENTS: 
 Title I: Report on Hospital-acquired vancomycin resistance 
 Title II: Identification of new vancomycin resistance strains 
 Title III: Reduction in cost-effectiveness of vancomycin resistance testing 
Title I: Report on Hospital-acquired vancomycin resistance
 - Amends the Federal Food, Drug, and Cosmetic Act to require that the report on hospital-acquired vancomycin resistance be based on analysis of 320 index m isolates and not on other factors. 
Title II: Identification of new vancomycin resistance strains
 - Declares that this report does not create new evidence of significant resistance to vancomycin. Calls for further research to determine whether new vancomycin resistance strains pose a significant threat to patients receiving vancomycin.
-----:49
TABLE OF CONTENTS: 
 Title I: Amendment to Food, Drug, and Cosmetic Act 
 Title II: Amendment to Medical Research Council Act of 1978 
 Title III: Amendments to the Public Health Service Act 
Title I: Amendment to Food, Drug, and Cosmetic Act
 - Amends the Food, Drug, and Cosmetic Act to modify the labeling of villiptin (formerly known as dpp-4-2005) to include a statement that the drug may cause changes in the absorption of villiptin and may cause changes in the function of certain renal cells. 
Title II: Amendment to Medical Research Council Act
 - Amends the Public Health Service Act to require the Secretary of Health and Human Services (HHS) to revise the guidelines for use of certain brand name drugs for maintenance treatment of diabetes to include statements that villiptin may cause changes in the absorption of villiptin and may cause changes in the function of certain renal cells.
-----:50
Infection with enterovirus serotypes involving a human embryo was conducted by: (1) sequencing the genome of such a virus; (2) using in vivo testing of such virus; and (3) altering the DNA of such virus to produce a different strain.
-----:51
Directs the Secretary of Health and Human Services to expand, intensify, and coordinate the activities of the National Institutes of Health related to the use of computed tomography in the diagnosis of aortic stenosis, and related monitoring and diagnostic procedures.
-----:52
Provides for the establishment of a study section to review the current state of knowledge concerning the treatment of traumatic brain injury to include: (1) the extent to which such injury is associated with other injuries and clinical outcomes; and (2) the extent to which such injury is associated with other injuries and clinical outcomes in patients with traumatic brain injury who were enrolled in the study and who did not receive appropriate treatment. Directs the Secretary of Health and Human Services, acting through the Administrator of the Health Resources and Services Administration, to conduct a study to: (1) review the current state of knowledge concerning the treatment of traumatic brain injury to include, among other things, the extent to which such injury is associated with other injuries and clinical outcomes in patients with traumatic brain injury who were enrolled in the study and who did not receive appropriate treatment; and (2) assess the current state of knowledge concerning the treatment of traumatic brain injury by means of both open and minimally invasive surgery, including traumatic brain injury treatment.
-----:53
Drug delivery systems using transhydrogenion permeation to produce patches with improved safety and effectiveness are proposed.
-----:54
Arthritis Research and Treatment Act of 2003 - Amends the Public Health Service Act to expand the scope of the Arthritis Research and Treatment Act to include research relating to physical activity and the treatment of rheumatoid arthritis.

Defines rheumatoid arthritis as a disease of the joints affecting an individual's muscles, tissues, and organs.

Requires the Secretary of Health and Human Services, acting through the Director of the Agency for Healthcare Research and Quality, to convene an independent panel of experts to review the current state of research relating to physical activity and the treatment of rheumatoid arthritis.

Requires the report to include specific recommendations on the provision of physical activity and rheumatoid arthritis treatment to individuals with the disease and on how best to provide for the delivery of such treatments to patients.
-----:55
TABLE OF CONTENTS: 
 Title I: Sugar Amendments to the Food, Drug, and Cosmetic Act 
 Title II: Sugar Amendments to the Food, Drug, and Cosmetic Act 
Food Amendments to the Food, Drug, and Cosmetic Act - 
Title I: Sugar Amendments to the Food, Drug, and Cosmetic Act
 - Amends the Federal Food, Drug, and Cosmetic Act to revise the definition of "salinity food" to include high fructose corn syrup. 
Title II: Sugar Amendments to the Food, Drug, and Cosmetic Act
 - Amends the Food, Drug, and Cosmetic Act to require manufacturers of all food ingredients to label the products with a statement that specifies: (1) the content; (2) the ratio of fructose to glucose in each product; (3) the number of calories in each product; (4) the concentration of fructose in the product; and (5) the source of the fructose. 
Requires the Secretary of Health and Human Services to issue a regulation that defines the term "salinity food" to mean any food containing high fructose (including corn, soybeans, and any other type of food), unless the Secretary determines that such food does not constitute a food subject to the Federal Food, Drug, and Cosmetic Act
-----:56
muscle fibers of the urinary tract, including mastichcazine treatment.
-----:57
Directs the Secretary of Health and Human Services, acting through the Administrator of the Health Resources and Services Administration, to enter into an agreement with the National Cancer Institute to conduct a study on the use of targeted therapeutic treatments for the prevention, diagnosis, and control of meningiomas.
-----:58
This bill amends the Public Health Service Act to modify the requirements for reporting certain instances of human papilloma patris disease to the Centers for Disease Control and Prevention. The bill also prohibits the Department of Health and Human Services from using the reporting requirements to assess or improve the clinical outcomes of patients with human papilloma patris disease.
-----:59
Amends the National Institute of Standards and Technology Act to require the Secretary of Health and Human Services to issue guidelines to assist laboratories in maintaining the stability of analytes of serum.
-----:60
United States Food and Drug Administration (FDA) Amends the Federal Food, Drug, and Cosmetic Act to require the labeling of food intended for human consumption to include the following statements: (1) in the case of milk, the content of each part of the food chain according to specified standards; (2) in the case of food intended for human consumption, the content of each part of the food chain according to specified standards; and (3) in the case of animal food, the content of each part of the food chain according to specified standards. 
Directs the Secretary of Health and Human Services to issue regulations to require that all labeling for food intended for human consumption include the following statements: (1) in the case of milk, the content of each part of the food chain according to specified standards; (2) in the case of food intended for human consumption, the content of each part of the food chain according to specified standards; and (3) in the case of animal food, the content of each part of the food chain according to specified standards.
-----:61
This report describes the collection of data on the conserved domains of the human genome for which certain predictions were made using the smart database. The conserved domains were restricted to five species of eu sapiens, the United States, Canada, and Mexico.
-----:62
Tuberculosis Research Act of 2011 - Amends the Public Health Service Act to require the Secretary of Health and Human Services (HHS) to conduct or support additional research to expand the understanding of the causes of tuberculosis.

Requires the Secretary to: (1) determine the prevalence of tuberculosis in Russia; (2) identify TB patients who received treatment for tuberculosis in Russia during the period of 2008 through 2010 and determine the susceptibility of such tuberculosis to various drugs and biological products; and (3) develop a tuberculosis drug resistance strategy.

Directs the Secretary to: (1) expand and intensify activities of the National Institute of Allergy and Infectious Diseases to research tuberculosis; (2) support research at the Center for Disease Control and Prevention (CDC) in Atlanta, Georgia, that includes the development of a tuberculosis vaccine; and (3) conduct additional research to determine the susceptibility of tuberculosis to various drugs and biological products.
-----:63
Prostate Cancer Redefines Pde5-is as a drug used to treat prostate cancer that is produced by the prostate cancer ( prostate cancer) and has been found to be effective in treating prostate cancer in vivo with respect to penile rehabilitation. Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary of Health and Human Services to issue regulations to increase the maximum dose of pde5-is that may be administered to a prostate cancer patient receiving pde5-is in a single administration.
-----:64
Requires the report to describe the effect of intermixing between specified layers of ingaas layers, the effect of intermixing on device performance, and the processing process used to achieve such an effect.
-----:65
TABLE OF CONTENTS: 
 Title I: Development, Manufacture, and Procurement 
 of Drugs 
 for Treatment of 
 infectious diseases 
 Title II: Development, Manufacture, and Procurement of Drugs 
 for Treatment of infectious diseases 
Title I: Development, Manufacture, and Procurement of Drugs for Treatment of Infectious Diseases
 - Amends the Food, Drug, and Cosmetic Act to require the Secretary of Health and Human Services to identify, develop, produce, and make available drugs which may be used to treat infectious diseases. Mandates the Secretary's approval of these drugs if they are approved by the Food and Drug Administration (FDA) and notimidazole-based drugs. 
Title II: Development, Manufacture, and Procurement of Drugs for Treatment of Infectious Diseases
 - Amends the Food, Drug, and Cosmetic Act to require the Secretary to identify, develop, produce, and make available drugs for treatment of infectious diseases which contain, or are derived from, specified chemicals. 
Title III: Development, Manufacture, and Procurement of Drugs for Treatment of Infectious Diseases
 - Requires the Secretary to determine the structure and characteristics of certain drugs for which a license has been issued by the Food and Drug Administration.
-----:66
Taxes income of a person who receives specified chemotherapy drugs for use in combination with radiation or radiation therapy for certain malignant tumors of the penile cells to be used separately for non-cancer purposes.
-----:67
Directs the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention (CDC), to initiate a national program to increase the number of physicians trained in the diagnosis of hook infection, particularly in rural areas, where the infection is more prevalent.

Authorizes the Secretary to provide technical assistance to CDC professionals in treating individuals with hook infection, to support the development and expansion of diagnostic tools, and to ensure that the resources available to the CDC are commensurate with the number of cases of hook infection that are reported to the National Institutes of Health (NIH).
-----:68
Directs the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention (CDC), to: (1) undertake a comprehensive study to determine the prevalence and clinical characteristics of ovov and the presence of other significant pathogens in children from a variety of sources, including enterobacteria, enterovirus, and influenza; and (2) report the results of such study to the appropriate congressional committees.
-----:69
Multicystic dysplastic kidney syndrome is a dominant condition that results from renal dysplasia and is associated with other multisystem disorders.
-----:70
Directs the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, to convene a panel of experts to review the current state of the science regarding the use of blood serum and other biological factors to determine whether additional studies should be conducted to determine the relationship between different risk factors for cardiovascular disease, including: (1) a review of the effect of certain therapeutic drugs on the development of chronic coronary heart disease; and (2) a review of the current state of knowledge regarding the role of immune system factors, including certain non-lethal factors, in the pathogenesis of cardiovascular disease.
-----:71
Prohibits the use of these compounds to treat human disease unless they are approved by the Food and Drug Administration. Requires that an investigational use application be submitted to the Secretary of Health and Human Services within six months of receiving it, and that the Secretary consider the application and issue a decision within 90 days.
-----:72
2014 Medical Care Research Advisory Board report on the use of a simplified method of replacing the tracheostomy tube with a tracheostomy set (which uses a brodoscopy rather than a needle) for patients with end stage renal disease.
-----:73
Directs the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to: (1) review the recommendations and guidelines of the Food and Drug Administration regarding the use of intravitreal injections for the treatment of neovascular degeneration, including recommendations relating to the safety and effectiveness of such injections; (2) take appropriate steps to ensure that such injections may be used for the treatment of other retinal conditions, as appropriate; and (3) review the recommendations and guidelines of the Food and Drug Administration regarding the use of intravitreal injections for the treatment of neovascular degeneration.
-----:74
Directs the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, to: (1) collect and analyze data on the extent to which glass ionomers of fluoride and carbamide were released into the water after bleaching and on the characteristics of the glass ionomers produced; and (2) make recommendations regarding the appropriate glass ionomer composition for both restorative and commercial uses.
-----:75
Directs the Secretary to report to the appropriate congressional committees on the status of the flexible brooscopy market, including the potential for its continued use and advancement in the field of pulmonary trauma treatment.
-----:76
metabolic syndrome is a simple measure of risk factors for diabetes and cardiovascular disease that is used to determine the risk of metabolic syndrome in the urban and rural populations of India.
-----:77
rheumatoid arthritis is a chronic disease where resident cells and mediators triggered through the expression of certain genes can induce periodontitis, a disease where the tissues are affected and the disease is caused by inflammation, certain bacteria, and periodontal disease. Authorizes the Secretary of Health and Human Services to provide certain reimbursements to the patient's physician for medical care incurred for the management of rheumatoid arthritis.
-----:78
Expresses the sense of the Congress that the Department of Health and Human Services should provide for the conduct and support of research into the incidence and incidence rates of prostate cancer in American men, and the reasons for the rising rates of such cancer, to determine the determinants of such rates and develop a plan to reduce and prevent them. Requires the Director of the Agency for Healthcare Research and Quality to: (1) conduct and support research to determine the incidence and incidence rates of prostate cancer in American men, and the reasons for the rising rates of such cancer, to determine the determinants of such rates and to develop a plan to reduce and prevent them; and (2) provide for the research funding of the above projects to continue and be supported by the resources and staff of the Agency for Healthcare Research and Quality.
-----:79
This bill authorizes the National Cancer Institute to conduct a pilot program to expand the understanding of the role of certain molecules in pediatric brain cancer. The program must: (1) identify new molecules that are expressed in micrornablastoma and may have a specific role in pediatric brain cancer, and (2) conduct research to determine the mechanisms by which such molecules interact with other molecules in the nervous system and how those molecules may be targeted for therapeutic purposes.
-----:80
This bill directs the Office of Medicine of the National Institutes of Health to initiate a study to evaluate the effect of electrotechpuncture on female subjects who were enrolled in a research program on anti- aging treatments.
-----:81
Directs the Secretary of Health and Human Services, acting through the Administrator of the Health Resources and Services Administration, to provide for the demonstration and thorough evaluation of the effect of the above above on the accuracy and the time required to provide patients with the results of acute coronary syndrome diagnostic tests.
-----:82
pancreatic pancreaticitis is a rare disease that causes inflammation, ulceration, and fibrosis of the pancreas, involving the fat cells. Allows the presence of pancreatic cancer, which is considered to be a Class I disease. Describes a case of pancreatic pancreaticitis that resulted in death.
-----:83
Laboratory Safety and Quality Management Act of 1998 - Provides for the establishment of a national system for the improvement of laboratory testing quality, based on certain principles, to reduce errors with poct (point-of-care testing). 
Requires each laboratory that receives Federal funds and is required to maintain a quality control plan to implement certain activities to reduce errors with poct. 
Directs the Secretary of Health and Human Services to provide for the establishment of a national system for the improvement of laboratory safety and quality control, based on certain principles, to reduce errors with poct. 
Requires a laboratory director to submit to the Secretary a plan for reducing errors with poct. Directs the Secretary to develop and maintain a database to track complaints regarding errors in laboratory testing and to provide incentives for laboratories to report complaints. 
Directs the Secretary to: (1) provide incentives for laboratories to report errors; and (2) develop and maintain a database to track the complaints of laboratory personnel with respect to poct.
-----:84
Allows the Secretary of Health and Human Services to determine which sports are considered to be engage in at-risk for injury based on the results of this survey.
Directs the Secretary to: (1) make grants to the Institute to assist it in conducting future surveys; and (2) establish a national data base to be known as the National Student Data System to provide the data needed for the creation of this report.
-----:85
Provides that, upon the recommendation of the Secretary of Health and Human Services, the Secretary shall: (1) review the evidence relating to the use of therapeutic hypothermia in patients following cardiac arrest for the purpose of determining whether it provides any additional protection against inflammatory and neurological effects following cardiac arrest, and (2) establish a panel to evaluate such evidence.
-----:86
Nuclear Waste Management Reform Act of 2005 - Amends the Nuclear Regulatory Commission Act to require the Secretary of Energy to submit to certain congressional committees a comprehensive plan for the long-term ( 10 year) storage of high level nuclear wastes in the deep subsurface, including: (1) a description of specified barrier design performance characteristics; (2) an analysis of the potential adverse effects of the proposed multi-barrier design; and (3) a comprehensive list of prohibited materials and activities.

Directs the Secretary to: (1) develop and implement a comprehensive plan to address specified issues at each site proposed to be managed by the Nuclear Regulatory Commission under the Act; (2) submit annual reports on progress made in implementing the plan, including an analysis of the potential adverse effects of the proposed multi-barrier design on life and the environment; (3) conduct a comprehensive study of the barriers at each site proposed to be managed by the Nuclear Regulatory Commission under the Act; and (4) submit to the Congress a plan to address specified issues arising from the proposed multi-barrier design.
-----:87
This bill directs the Agency for Healthcare Research and Quality to award grants to support research efforts to develop a uniform approach to analyze the immune response of pregnant women during the first week of pregnancy and beyond, in order to determine the determinants of maternal immune response and placental tissue expression during the first week of pregnancy, before and after delivery, and in the postnatal period. The Government Accountability Office must review the results of these efforts and identify any gaps in this research.
-----:88
Expresses the sense of the Congress that: (1) the Secretary should initiate a study to determine the relationship between vitamin E and oxygen free radical damage caused by resistance exercise; and (2) a report should be submitted to the Congress containing the results of such study within one year.
-----:89
Directs the Secretary of Health and Human Services to establish a national registry of qualified glaucoma patients to determine the prevalence and incidence of glaucoma, and the treatment options available to them. Requires the Secretary, acting through the Director of the National Institutes of Health, to report to the Congress on the collection and storage of glaucoma samples, the ionization levels of those samples, and the effectiveness of the glaucoma screening program administered by the Centers for Disease Control and Prevention.
-----:90
Directs the Secretary of Health and Human Services (HHS) to establish and implement a comprehensive strategy to improve the identification, research, and dissemination of information on the incidence, prevalence, and circumstances of migraine in patients with asthma.
-----:91
Directs the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention, to: (1) undertake research and development projects to improve the safety of bracket bonding systems, including investigating methods and technologies to reduce the risk of cracks that may occur during the bonding process; and (2) provide grants to institutions of higher education for research to determine how best to develop technologies to reduce the risk of cracks during bracket bonding.
-----:92
osteolasts are highly specialized cells responsible for the dissolution of organic bone progenitors and their sorting through various protein trafficking groups. This article describes the role of osteolasts in hereditary bone diseases, including how a certain protein encoded by the osteolasts acts in bone tissue.
-----:93
Requires the Secretary, acting through the Director of the National Institutes of Health, to report to the appropriate congressional committees regarding the extent to which the variations reported in this report are consistent with the results of other studies regarding cnvs in the human genome.
-----:94
Directs the Secretary of Health and Human Services, acting through the Director of the Centers for Disease Control and Prevention (CDC), to make grants to support research to: (1) identify the role of certain transcription factors in the pathogenesis of secondary brain injury following traumatic brain injury; and (2) evaluate the effectiveness of current medical treatments in preventing, treating, and rehabilitating such injury.
-----:95
Big Data in Critical Care discusses the use of data in critical care and presents proposals for integrating big data into a clinical practice system.
-----:96
Antibiogram of enterococcus aureus - Amends the Federal Food, Drug, and Cosmetic Act to require that specified hospitals and laboratories report monthly to the Secretary of Health and Human Services on antimicrobial drug-resistant faecococcus isolates tested.
-----:97
Preliminary results from the 2010 H1n1 pandemic influenza surveillance study are provided, including estimates of the incidence and prevalence of ph1n1associated hospitalizations and deaths in all states and U.S. territories.
-----:98
bilateral shoulder dislocations are most type of trauma without any traumatic seizure disorder and are usually associated with post-traumatic seizure disorder or simultaneous bilateral dislocations.

 report a case of mid-traumatic shoulder dislocation without associated trauma in 45 years of old women presented to hospital by new shoulder trauma in which the dislocation was followed by a previous traumatic shoulder injury which was abducted by the right shoulder with increased vertical diameter of elbow, and was subsequently revealed to be a result of bilateral dislocation of the left shoulder.




Vests in the right shoulder an index shoulder with atraumatic seizure disorder or simultaneous bilateral dislocation of the left shoulder by force of TBI.
-----:99
Directs the Secretary of Health and Human Services (HHS) to provide financial assistance to the National Institute of Diabetes and Digestive and Kidney Diseases to conduct or support research to determine the relationship between body weight, height, and disease at birth, and long-term health status in the National Diabetes Cohort Study.
